Di Deo, A.; Oosterholt, S.; Horrigan, J.; Evans, S.; McMorn, A.; Della Pasqua, O.
Population Pharmacokinetics of Tideglusib in Congenital and Childhood Myotonic Dystrophy Type 1: Influence of Demographic and Clinical Factors on Systemic Exposure. Pharmaceutics 2025, 17, 1065.
https://doi.org/10.3390/pharmaceutics17081065
AMA Style
Di Deo A, Oosterholt S, Horrigan J, Evans S, McMorn A, Della Pasqua O.
Population Pharmacokinetics of Tideglusib in Congenital and Childhood Myotonic Dystrophy Type 1: Influence of Demographic and Clinical Factors on Systemic Exposure. Pharmaceutics. 2025; 17(8):1065.
https://doi.org/10.3390/pharmaceutics17081065
Chicago/Turabian Style
Di Deo, Alessandro, Sean Oosterholt, Joseph Horrigan, Stuart Evans, Alison McMorn, and Oscar Della Pasqua.
2025. "Population Pharmacokinetics of Tideglusib in Congenital and Childhood Myotonic Dystrophy Type 1: Influence of Demographic and Clinical Factors on Systemic Exposure" Pharmaceutics 17, no. 8: 1065.
https://doi.org/10.3390/pharmaceutics17081065
APA Style
Di Deo, A., Oosterholt, S., Horrigan, J., Evans, S., McMorn, A., & Della Pasqua, O.
(2025). Population Pharmacokinetics of Tideglusib in Congenital and Childhood Myotonic Dystrophy Type 1: Influence of Demographic and Clinical Factors on Systemic Exposure. Pharmaceutics, 17(8), 1065.
https://doi.org/10.3390/pharmaceutics17081065